Four Anchorage Men Diagnosed With Mpox Without Travel History, Alaska Health Confirms

Four Anchorage men diagnosed with mpox since late October share a detail that has epidemiologists leaning forward: none reported travel outside Alaska, Homer News reported.

The cluster, confirmed by the Alaska Department of Health on Oct. 29 and Nov. 5, represents the state’s first infections involving the clade Ib strain and its highest annual count since the 2022 outbreak. Two of the initial three patients were partners infected with clade Ib; one was briefly hospitalized. The fourth case brought Alaska’s 2025 total to four, compared with only two cases recorded statewide between 2023 and 2025.

He told the Juneau Empire it remains too early to conclude the virus is circulating regularly in Alaska.

Alaska’s cluster is not an isolated flare-up. The Centers for Disease Control and Prevention has logged more than 200 laboratory-confirmed clade I infections across at least 31 states and Puerto Rico since November 2024, with possible local transmission now reported in 16 U.S. jurisdictions. An August CDC report also documented that clade IIb — the strain behind the 2022 global outbreak — continued spreading at low levels through 2024 and 2025.

“It’s too early to draw that conclusion,” Costa said when asked if the virus could begin circulating regularly in Alaska.

Clade I has historically caused more severe illness than clade II, though recent clade Ib outbreaks in Central and Eastern Africa have shown death rates below 0.5 percent in areas with medical care, according to CDC estimates. Most U.S. patients have experienced mild illness, but people with severely weakened immune systems — particularly those with advanced or untreated HIV — face a higher risk of serious complications.

The Anchorage cases have exposed a practical problem: Alaska’s two-dose completion rate. CDC studies estimate effectiveness at 66 percent to 90 percent after both doses, with protection peaking roughly two weeks after the second injection.

The vaccine is also an option after exposure. The CDC recommends a first dose within four days of a known or suspected exposure when possible; vaccination between four and 14 days afterward may still reduce the likelihood or severity of illness.

Jynneos became commercially available in 2024 and was added to the adult immunization schedule that year, meaning most private insurance plans, Medicare Part D and Medicaid cover it at no cost to eligible patients.

The virus spreads mainly through direct contact with infectious skin lesions or bodily fluids, often during sexual or other intimate contact. Transmission through prolonged close contact or contaminated bedding and clothing is possible, but brief casual interactions have not been documented as a route.

Some patients develop the rash without earlier symptoms. People remain infectious for two to four weeks, until all lesions have healed and new skin has formed.

The Alaska Department of Health was established in 2022, when Governor Mike Dunleavy reorganized the former Department of Health and Social Services into two agencies.

Commissioner Heidi Hedberg, who has served within the department since 2009 and led the Division of Public Health as Director beginning in 2019, was appointed to lead the new department later that year. The agency manages health care services, public assistance programs, and public health, including overseeing rules, licensing facilities, and enforcing Medicaid and state regulations.

Costa said some healthcare providers may not know Jynneos is now commercially available and on the adult schedule. He urged clinicians to discuss mpox during sexual health appointments, particularly those involving sexually transmitted infections or HIV prevention medication. Not everyone will need the vaccine, he said, but those conversations can identify patients who would benefit.